To foster continuous enhancement in clinical care and public health delivery, two pivotal incentive schemes drive positive change: The Quality and Outcomes Framework (QOF) and the Investment and Impact Fund (IIF)
In England, general practices are incentivised through 2 main schemes, the:
Quality and Outcomes Framework (QOF)
Investment and Impact Fund (IIF)
These schemes aim to enhance healthcare delivery and patient outcomes by incentivising continuous improvement in clinical care and public health delivery.
As the government aims to reshape healthcare incentives, they’re turning to you for guidance. The consultation window remains open until March 7th, and your insights can be the compass for change.
This consultation is divided into 3 sections:
feedback on the role and nature of any incentive scheme in general practice, with a focus on the current scope of the QOF and the IIF
comments on possible changes in the scope of incentive schemes beyond clinical indicators
input on reducing the administrative burden associated with the schemes and enhancing the clinician’s experience of delivering it
This consultation aims to gather diverse views and is open to all stakeholders, including healthcare professionals, patient groups and the wider public.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment